- Home
- STT vs RVMD Comparison
STT vs RVMD Comparison
Compare STT & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | STT | RVMD |
|---|---|---|
| Founded | 1792 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.6B | 42.8B |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | STT | RVMD |
|---|---|---|
| Price | $177.03 | $205.17 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 19 |
| Target Price | ★ $148.86 | $140.84 |
| AVG Volume (30 Days) | 1.5M | ★ 1.6M |
| Earning Date | 04-17-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.23% | N/A |
| EPS Growth | ★ 14.49 | N/A |
| EPS | ★ 6.14 | N/A |
| Revenue | ★ $13,944,000,000.00 | N/A |
| Revenue This Year | $7.66 | N/A |
| Revenue Next Year | $3.87 | $533.02 |
| P/E Ratio | $28.83 | ★ N/A |
| Revenue Growth | ★ 7.26 | N/A |
| 52 Week Low | $104.64 | $45.61 |
| 52 Week High | $195.93 | $224.31 |
Technical Indicators
Market Signals| Indicator | STT | RVMD |
|---|---|---|
| Relative Strength Index (RSI) | 34.05 | 49.62 |
| Support Level | $175.50 | $198.91 |
| Resistance Level | $194.76 | $222.33 |
| Average True Range (ATR) | 3.91 | 7.48 |
| MACD | -1.12 | -0.12 |
| Stochastic Oscillator | 3.15 | 53.79 |
Price Performance
Historical ComparisonAbout STT State Street Corporation
State Street is a leading provider of financial services, including investment servicing, investment management, and investment research and trading. With approximately $54 trillion in assets under custody and administration, and $5.7 trillion in assets under management, as of Dec. 31, 2025, State Street operates globally in more than 100 geographic markets and employs about 51,500 worldwide.
About RVMD Revolution Medicines Inc.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.